I called 2 TA Sciences resources yesterday. They gave me the current protocol/'Patton Program' for using TA-65/Cylcoastragenol to lengthen telomeres. They start out at 25mg for a few days (7), then suggest 50mg for 3 months, then 100 mg for another 3 months. Then a break. The pulsatile/break thing is up for grabs at the moment as far as the best way to coax your telomeres to grow a bit and still have your cells be sensitive to this stimuli. After about a year on this regimen and the best-case scenario is that your telomeres have lengthened to the extent that you've gotten back a good decade of your life on earth.
I believe, since this company's initial program had dosing at 5 mg a day, that someone here was interested in knowing whether this new regimen offered a new 'molecule'. Well, if they did, a lot of people who are paying and considering paying 4k for every 6 months for the recommended 3 years of treatment for the least pricey plan wouldn't be happy. And even though some of these customers might be too busy to check, and some of these customers may not be knowledgeable labrats, some indeed aren't and are.
http://www.wipo.int/...mp;DISPLAY=DESC
The above link is from a Geron patent description. The best paragraph (as most best paragraphs are) is about 4/5 of the way down the page. It has to do with dosing--
<For treatment of a subject or patient, such as a mammal or a human patient, dosages are determined based on factors such as the weight
and overall health of the subject, the condition treated, severity of symptoms, etc. Dosages and concentrations are determined to
produce the desired benefit while avoiding any undesirable side effects. Typical dosages of the subject compounds are in the range
of about 0 5 to 500 mg/day for a human patient, preferably about 1-100 mg/day. For example, higher dose regimens
include e. g. 50-100,75-100, or 50-75 mg/day, and lower dose regimens include e. g. 1-50, 25-50, or 1-25 mg/day.
In specific embodiments, for example, the compound designated herein as 2 (cycloastragenol) is administered at a
level of at least 1 mg/day, preferably at least 5 mg/day; or the compound designated herein as 1 (astragaloside IV)
is administered at a level of at least 50 mg/day, preferably at least 100 mg/day. >
So, I personally think that TA is using Astral. IV. And they can do so, I suppose, because 'TA-65' is in it--somewhere. I haven't parsed their marketing, but I'm sure they have.
Their rationale may be that they are simply performing another leg of an IND type of experimentation (for another company). Just that I wouldn't expect a company who paid Geron for the use of its patented miracle to do this. Perhaps in using this form of the TA, they are trying to avoid serious side effects(ca)/lawsuits and providing a greater margin of safety. Their program would still be desired by those who would appreciate/need carriage-trade style care.
Edited by Lesbure, 12 December 2009 - 09:25 AM.
